OVERVIEW
Happy Saturday
Welcome to the Stocks Top 25 Newsletter this week!
Last week, many of you noticed our numbers were out of whack, so this week we are starting over: fresh lists of the top performers so far this year. We are including the comparative momentum meter to show the total return if you had already owned these stocks so far this year, and how they would have performed.
This year, expect better graphs! We are working on back end tricks to make these momentum lists better than ever, so stay tuned!
The Stocks Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date and tracks their performances over time. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!
Here are the Stocks Top 25 Lists for this week:
S&P 500
Top 25 S&P 500
The S&P 500 Top 25 list came up 4.87%compared to the weekly S&P 500 index -0.35%
NASDAQ 100
The Large-Cap Nasdaq 100
The Nasdaq 100 Top 25 list performed 2.42% compared to the weekly Nasdaq 100 index 0.30%
RUSSELL 2000
The Growth-Centric Russell 2000
The Russell 2000 Top 25 list was 19.23% compared to the weekly Russell 2000 index -0.32%
Top Dawg Of The Week
The Top 25 list's Top Dawg was $CRVS ( ▼ 1.65% ) , climbing an insane 211%!
Corvus Pharmaceuticals experienced an explosive rally this week primarily due to breakthrough clinical trial data for soquelitinib, its oral treatment for atopic dermatitis (eczema). On Tuesday, the company reported that patients in its Phase 1 "Cohort 4" study saw a 72% reduction in eczema severity after eight weeks of treatment, significantly outperforming the placebo group. This data was viewed by analysts as "best-in-class," suggesting the pill could eventually compete with or surpass leading injectable biologics like Dupixent.
The massive surge in share price, which at one point saw the stock more than double, allowed the company to immediately capitalize on the momentum with a major capital raise. Corvus successfully priced and closed an upsized public offering today, raising approximately $201 million. Investors responded positively to this move because it provides the company with a significant cash runway to fund upcoming Phase 2 and Phase 3 trials, effectively removing the immediate "cash burn" risk that often weighs on clinical-stage biotech stocks.
